Beam Therapeutics (BEAM) Notes Payables (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Notes Payables data on file, last reported at $5.2 million in Q1 2026.

• On a quarterly basis, Notes Payables changed 0.0% year-over-year to $5.2 million in Q1 2026; TTM through Mar 2026 was $5.2 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $7.7 million, down 8.33% from the prior year.
• Notes Payables for Q1 2026 stood at $5.2 million, down from $7.7 million in the prior quarter.
• Over the last five years, Notes Payables for BEAM reached as high as $28.6 million in Q1 2022 and fell as low as $3.9 million in Q2 2025.
• Historically, Notes Payables has averaged $11.6 million across 5 years, with a median of $8.9 million in 2023.
• Across the five-year window, Notes Payables sank 80.8% in 2022 and grew 7.87% in 2024, its largest moves.
• Year by year, Notes Payables stood at $18.3 million in 2022, then sank by 40.98% to $10.8 million in 2023, then dropped by 22.22% to $8.4 million in 2024, then decreased by 8.33% to $7.7 million in 2025, then plunged by 32.47% to $5.2 million in 2026.
• Per Business Quant data, the three most recent Notes Payables figures were $5.2 million in Q1 2026, $7.7 million in Q4 2025, and $6.5 million in Q3 2025.